AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,409 | -25.2% | 120,363 | -39.3% | 0.03% | -26.3% |
| Q1 2023 | $4,556 | +1056.3% | 198,366 | +1314.4% | 0.04% | +533.3% |
| Q4 2022 | $394 | -100.0% | 14,025 | -76.7% | 0.01% | -62.5% |
| Q2 2022 | $1,335,000 | -72.5% | 60,238 | -63.8% | 0.02% | -73.8% |
| Q1 2022 | $4,846,000 | +1220.4% | 166,459 | +1390.0% | 0.06% | +1425.0% |
| Q4 2021 | $367,000 | -68.2% | 11,172 | -55.3% | 0.00% | -75.0% |
| Q3 2021 | $1,153,000 | +428.9% | 24,978 | +530.4% | 0.02% | +700.0% |
| Q2 2021 | $218,000 | -93.9% | 3,962 | -94.2% | 0.00% | -96.2% |
| Q1 2021 | $3,546,000 | +14.3% | 68,673 | -4.1% | 0.05% | +73.3% |
| Q4 2020 | $3,102,000 | +197.7% | 71,601 | +140.5% | 0.03% | +42.9% |
| Q3 2020 | $1,042,000 | -67.5% | 29,772 | -50.3% | 0.02% | -74.7% |
| Q2 2020 | $3,204,000 | +276.5% | 59,908 | +374.7% | 0.08% | +31.7% |
| Q1 2019 | $851,000 | – | 12,621 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |